EBITDA Margin % is calculated as EBITDA divided by its Revenue. Transgenic Group's EBITDA for the
six
months ended in Mar. 2026 was 円-164 Mil. Transgenic Group's Revenue for the
six
months ended in Mar. 2026 was 円6,950 Mil. Therefore, Transgenic Group's EBITDA margin for the quarter that ended in Mar. 2026 was -2.36%.
Transgenic Group (TSE:2342) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Transgenic Group EBITDA Margin % Related Terms
Transgenic Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Transgenic Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Transgenic Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Transgenic Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a EBITDA Margin % of -2.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Transgenic Group and its competitors. According to the industry distribution chart, Transgenic Group ranks #304 out of 943 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Transgenic Group's EBITDA Margin % too high?
Transgenic Group's current EBITDA Margin % is -2.36%. Based on the distribution chart, Transgenic Group ranks #304 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Transgenic Group has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #304 out of 943 companies for EBITDA Margin %. This puts Transgenic Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Transgenic Group and its competitors. Transgenic Group's current EBITDA Margin % is -2.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.18, compared to a current price of 円207.00 — trading 19.5% below its estimated fair value. The current EBITDA Margin % is -2.36%. Transgenic Group's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current EBITDA Margin % is -2.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円207.00 is trading 19.5% below its estimated GF Value™ of 円257.18.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
EBITDA Margin %: -2.36%
GF Value™: 円257.18 vs. price of 円207.00 (19.5% below fair value)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
59GF Score
Get the complete analysis for TSE:2342
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
